Skip to content Skip to footer
Viewpoints_Priya Singhal

Priya Singhal, Senior Vice President at Biogen, Shares Insights from Litifilimab Systemic Lupus Erythematosus NEJM Publication

Shots: Priya spoke about the study design and key findings from the P-II (LILAC), P-III (TOPAZ-1) & (TOPAZ-2) clinical study evaluating litifilimab She also talked about the P-III trial evaluating Dapirolizumab pegol in collaboration with UCB to treat SLE The interview summarizes how Biogen’s innovative medications are helping patients with Systemic Lupus Erythematosus which has…

Read more

PharmaShots Interview GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus

PharmaShots Interview: GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus

In an interview with PharmaShots, Angela Carroll, US Medical Affairs Scientific Director-Immuno-inflammation at GSK shared her views on a first published article on disease modification in systemic lupus erythematosus, published in Lupus Science & Medicine Shots: The company has published the first research to define disease modification in SLE including LN in the Lupus Science & Medicine. In multiple therapeutic…

Read more